Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

Paul W H I Parren, Thomas Geisbert, Toshiaki Maruyama, Peter B. Jahrling, Dennis R. Burton

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

Original languageEnglish (US)
Pages (from-to)6408-6412
Number of pages5
JournalJournal of Virology
Volume76
Issue number12
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Viremia
viremia
Neutralizing Antibodies
neutralization
Zaire Ebola virus
disease control
Animal Models
animal models
antibodies
Antibodies
neutralization tests
infection
guinea pigs
monoclonal antibodies
Guinea Pigs
Monoclonal Antibodies
Viruses
dosage

ASJC Scopus subject areas

  • Immunology

Cite this

Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. / Parren, Paul W H I; Geisbert, Thomas; Maruyama, Toshiaki; Jahrling, Peter B.; Burton, Dennis R.

In: Journal of Virology, Vol. 76, No. 12, 2002, p. 6408-6412.

Research output: Contribution to journalArticle

Parren, Paul W H I ; Geisbert, Thomas ; Maruyama, Toshiaki ; Jahrling, Peter B. ; Burton, Dennis R. / Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. In: Journal of Virology. 2002 ; Vol. 76, No. 12. pp. 6408-6412.
@article{c1981c21438b4289aa9c616e0b537549,
title = "Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody",
abstract = "A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.",
author = "Parren, {Paul W H I} and Thomas Geisbert and Toshiaki Maruyama and Jahrling, {Peter B.} and Burton, {Dennis R.}",
year = "2002",
doi = "10.1128/JVI.76.12.6408-6412.2002",
language = "English (US)",
volume = "76",
pages = "6408--6412",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

AU - Parren, Paul W H I

AU - Geisbert, Thomas

AU - Maruyama, Toshiaki

AU - Jahrling, Peter B.

AU - Burton, Dennis R.

PY - 2002

Y1 - 2002

N2 - A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

AB - A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

UR - http://www.scopus.com/inward/record.url?scp=0036100307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036100307&partnerID=8YFLogxK

U2 - 10.1128/JVI.76.12.6408-6412.2002

DO - 10.1128/JVI.76.12.6408-6412.2002

M3 - Article

VL - 76

SP - 6408

EP - 6412

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 12

ER -